Multiple endocrine neoplasia type 2 other imaging findings

	Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Multiple endocrine neoplasia type 2 other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 2 other imaging findings
CDC on Multiple endocrine neoplasia type 2 other imaging findings
Multiple endocrine neoplasia type 2 other imaging findings in the news
Blogs on Multiple endocrine neoplasia type 2 other imaging findings
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Radioactive iodine: lesions do not concentrate radioactive iodine since the tumour does not arise from thyroid follicular cells.
FDG-PET: avid uptake
Tl-201: It has been shown to concentrate Thallium-201^[1]
I-123 MIBG: 30% of MTCs show uptake if the thyroid is blocked with Lugol solution prior to the scan

[18F]-fluorodopamine ([18F]DA) PET is the best imaging modality for pheochromocytoma
MIBG (123I- or 131I- metaiodobenzylguanidine) scintigraphy is another imaging modality for pheochromocytoma

99mTc-sestamibi scintigraphy is a good imaging modality for hyperparathyroidism.

↑ Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH (1985). "Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy". Surgery. 98 (6): 1189–96. PMID 2866591.
↑ "http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/7932">rID: 7932
↑ "http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/16148">rID: 16148